Want to see ANVS full AI Analyst Report?
ANVS Stock Chart & Stats
$1.78
<$0.01(0.60%)
At close: 4:00 PM EDT
$1.78
<$0.01(0.60%)
Day’s Range― - ―
52-Week Range$0.95 - $5.50
Previous Close$1.67
Volume499.66K
Average Volume (3M)934.69K
Market Cap
$40.97M
Enterprise Value$51.06M
Total Cash (Recent Filing)$18.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Nov 11, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding42,679,058
10 Day Avg. Volume633,877
30 Day Avg. Volume934,691
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-2.78
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.04
Forecast
1Y Price Target
$10.67Price Target Upside499.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Neurodegenerative PipelineA focused pipeline targeting major neurodegenerative diseases gives Annovis a clear strategic identity and exposure to substantial unmet medical needs. Concentrating research and development on these indications may help align clinical expertise, regulatory planning, and capital allocation around a coherent long-term opportunity.
Phase 3 Execution MilestoneCompleting enrollment in a pivotal Alzheimer’s Phase 3 trial is a meaningful development milestone that advances the lead program toward important clinical readouts. This reduces execution uncertainty relative to earlier development stages and creates a defined pathway for assessing the candidate’s potential.
No Reported DebtThe absence of reported debt limits refinancing obligations and interest-rate exposure, preserving more flexibility than a similarly loss-making company with material leverage. This can help management direct available resources toward clinical development rather than scheduled debt service or creditor constraints.
Bears Say
No Commercial RevenueThe absence of revenue across multiple reporting periods shows that the company has not yet demonstrated commercial traction or a recurring source of operating income. Until a product reaches the market and generates sales, progress remains dependent on clinical success, regulatory outcomes, and external funding.
Intensifying Cash BurnPersistent negative operating and free cash flow means the business is consuming cash to fund operations rather than financing development internally. The sharper TTM deterioration increases the likelihood that additional capital will be needed, potentially constraining strategy or creating dilution pressure.
Weakening Balance SheetEpisodes of negative equity and a meaningful decline in total assets indicate that cumulative losses are eroding the balance sheet despite the lack of reported debt. Reduced asset support can limit financial resilience and leave fewer resources available to absorb setbacks or sustain development.
Annovis Bio News
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $0.95 and its highest was $5.50 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $40.97M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 14, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.453 by $0.053.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.3.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 42,679,058 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.453. Following the earnings report the stock price went up 3.352%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (499.25% Upside)
$10.67 (499.25% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.51%
12-Months-Change
Fundamentals
Return on Equity
-685.96%
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Annovis Bio
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$10.67
▲(499.25% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
11.28% Insiders
2.59% Mutual Funds
0.29% Other Institutional Investors
81.88% Public Companies and
Individual Investors